| Previous close | 44.24 |
| Open | 44.24 |
| Bid | 40.10 |
| Ask | 47.20 |
| Strike | 220.00 |
| Expiry date | 2025-01-17 |
| Day's range | 44.24 - 52.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
PR NewswireIllumina's planned divestment of GRAIL approved by the European Commission
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).
- Reuters
UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail
U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.
ReutersEU approves Illumina's plan to divest cancer test maker Grail
BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.
